0001493152-24-007456.txt : 20240221
0001493152-24-007456.hdr.sgml : 20240221
20240221193058
ACCESSION NUMBER: 0001493152-24-007456
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240220
FILED AS OF DATE: 20240221
DATE AS OF CHANGE: 20240221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SAHAREK JOHN P.
CENTRAL INDEX KEY: 0001632091
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35814
FILM NUMBER: 24661791
MAIL ADDRESS:
STREET 1: 12264 EL CAMINO REAL
STREET 2: SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER NAME:
FORMER CONFORMED NAME: Saharek John
DATE OF NAME CHANGE: 20150128
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: HARROW, INC.
CENTRAL INDEX KEY: 0001360214
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 450567010
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 102 WOODMONT BLVD
STREET 2: SUITE 610
CITY: NASHVILLE
STATE: TN
ZIP: 37215
BUSINESS PHONE: 615.733.4731
MAIL ADDRESS:
STREET 1: 102 WOODMONT BLVD
STREET 2: SUITE 610
CITY: NASHVILLE
STATE: TN
ZIP: 37215
FORMER COMPANY:
FORMER CONFORMED NAME: HARROW HEALTH, INC.
DATE OF NAME CHANGE: 20181228
FORMER COMPANY:
FORMER CONFORMED NAME: Imprimis Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20120301
FORMER COMPANY:
FORMER CONFORMED NAME: TRANSDEL PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20070912
4
1
ownership.xml
X0508
4
2024-02-20
0
0001360214
HARROW, INC.
HROW
0001632091
SAHAREK JOHN P.
C/O HARROW HEALTH, INC.
102 WOODMONT BLVD, SUITE 610
NASHVILLE
TN
37205
0
1
0
0
CEO of ImprimisRx
0
Common stock
2024-02-20
4
M
0
30000
10.67
A
262419
D
Common stock
2024-02-20
4
M
0
12616
10.67
D
249803
D
RSU
0.00
2024-02-20
4
M
0
30000
0
D
Common Stock
30000
0
D
The listed acquired 30,000 shares of Harrow, Inc. ("Harrow")_common stock represent restricted stock units (RSUs") granted to Mr. Saharek on February 19, 2021 under the Issuer's 2017 Stock Incentive and Awards Plan, as amended. The RSUs vested after a three-year period following the award date. 12,616 shares of Harrow common stock listed as disposed were withheld from issuance by Harrow to satisfy Mr. Saharek's payroll tax liability incident related to the vesting of the RSUs. Such withholding did not involve any market sales or other market transactions.
/s/ John P. Saharek
2024-02-21